Loyal for Dogs LOY-001: Where the Research Stands

LOY-001 is an investigational injectable drug candidate from Loyal (legal name Cellular Longevity, Inc.), developed with the goal of extending healthy lifespan in large and giant breed dogs by lowering circulating IGF-1. It is not an FDA-approved veterinary drug, it is not something your vet can prescribe today, and it is not sold anywhere. Loyal is a privately held, venture-backed company, so there is no LOY-001 ticker symbol and no public shares to buy. Senolytics — the other canine longevity category owners keep running into — sit in a similar place: biologically interesting, actively studied, not approved for dogs.

Here is what is actually known, what is still being worked out in the regulatory pipeline, and what owners are doing for their dogs' mobility in the meantime.

What LOY-001 is designed to do

Start with the observation that drives the whole program. In dogs, body size and lifespan run in opposite directions. Small breeds routinely live into their mid-teens; giant breeds often don't reach double digits. That inverse relationship is one of the better-documented patterns in canine biology, and it is unusual — across species, bigger animals generally live longer, not shorter.

One of the leading explanations involves insulin-like growth factor 1 (IGF-1), a hormone central to growth signalling. Large dogs carry higher circulating IGF-1 than small dogs, and elevated growth signalling has been linked in multiple species to faster aging. LOY-001 is built around that hypothesis: reduce IGF-1 in large-breed dogs toward levels closer to what smaller dogs carry, and potentially shift the aging trajectory.

It is designed as a long-acting injection given at a veterinary clinic rather than a daily pill. Loyal has also described LOY-003, an oral candidate aimed at the same IGF-1 pathway for large dogs, and LOY-002, a daily pill aimed at senior dogs across size ranges through a different mechanism related to metabolic health.

The important nuance: none of these is a treatment for a disease. They are aimed at healthspan and lifespan in otherwise healthy dogs, which is precisely what makes the regulatory path unusual.

Where LOY-001 sits in the FDA process

Animal drugs go through the FDA's Center for Veterinary Medicine (CVM). A sponsor has to satisfy three main pillars: effectiveness, safety, and manufacturing quality (CMC). Full approval requires all three.

There is also a conditional approval pathway. Under it, a drug may be legally marketed before the full effectiveness demonstration is complete, provided the sponsor has shown a reasonable expectation of effectiveness and has satisfied safety and manufacturing requirements. Conditional approval is renewed annually and is time-limited — the sponsor must complete the full effectiveness work within that window or lose the authorisation. That framework is set in regulation, not in press releases, and it is the route Loyal has publicly pursued.

In November 2023, Loyal announced that FDA CVM had concluded there was a reasonable expectation of effectiveness for LOY-001 — a genuine milestone, and the first of its kind for a canine longevity drug. Loyal has since announced a comparable effectiveness milestone for LOY-002, which has been studied in a large placebo-controlled trial in senior dogs. Neither milestone is an approval. It is one pillar of three.

Regulatory status changes without much warning, and plenty of secondhand coverage gets it wrong. Before you assume anything about availability, check Loyal's own announcements and FDA CVM's published materials rather than a news aggregator or a forum post.

Can you buy Loyal or LOY-001 stock?

No. Loyal is a private company funded through venture rounds. It has no listing on a public exchange, which means there is no LOY-001 stock, no ticker, and no legitimate way for a retail investor to buy in through a brokerage account.

This matters beyond curiosity. High-interest private biotech names attract impersonation — fake pre-IPO share offers, social media accounts promising allocations, cloned websites collecting deposits. If someone is offering you shares in a canine longevity company, treat that as a red flag until proven otherwise. Private company financing status can change, so verify through primary sources and registered exchanges, never through an inbound message.

Senolytics for dogs: what the category actually is

As animals age, some cells stop dividing but refuse to die. These senescent cells linger and secrete a cocktail of inflammatory signals — the senescence-associated secretory phenotype, or SASP — that degrades the tissue around them. Senescent cells accumulate in joints, tendons, skin, and organ tissue over a lifetime, and research links that accumulation to many of the functional declines owners recognise as 'getting old': stiffness, slower recovery, reduced tissue resilience.

Senolytics are compounds that selectively clear those cells. The two most discussed candidates are the combination of dasatinib and quercetin, and fisetin, a flavonoid found in strawberries and other plants. Most of the underlying evidence comes from laboratory rodent work and early human trials. Canine-specific data is thin, and no senolytic has FDA approval for use in dogs.

Two cautions deserve emphasis. Dasatinib is a prescription human cancer drug with a serious side-effect profile — it is not something to source or improvise with at home under any circumstances. And fisetin sold as a supplement is not the same thing as a dosed, characterised clinical intervention; the supplement aisle is largely unregulated for potency and purity. If senolytics interest you for an aging dog, that is a conversation to have with your veterinarian, not a purchase to make from a marketplace listing.

It is also worth separating senolytics from rapamycin, which gets lumped in with them. Rapamycin is an mTOR inhibitor — it modulates growth and nutrient-sensing signalling rather than clearing senescent cells. It has been studied in companion dogs through the Dog Aging Project's randomised, placebo-controlled trial arm. Different mechanism, different evidence base, same unapproved status for longevity use.

The longevity pipeline versus what owners can actually use today

Approach	Mechanism	Regulatory status for dogs	Available to owners now?
LOY-001 (injectable)	Lowers IGF-1 in large/giant breeds	Investigational; effectiveness milestone announced, not approved	No
LOY-002 (daily pill)	Metabolic pathway in senior dogs	Investigational; effectiveness milestone announced, not approved	No
Senolytics (fisetin, dasatinib + quercetin)	Clears senescent cells	No FDA approval for canine longevity use	Only as human-market compounds; not advisable without veterinary oversight
Rapamycin	mTOR inhibition	Studied in companion-dog trials; not approved for longevity	Trial settings and off-label veterinary decisions only
K9-REPAIR (BPC-157 + TB-500)	Peptides studied for tissue repair signalling and cell migration	Supplement; not an FDA-approved veterinary drug	Yes, direct to door from pawgen

No longevity drug for dogs has full FDA approval, and nothing in the pipeline replaces the three things that most reliably shape how a dog ages: a lean body weight, consistent conditioning, and early veterinary attention when something changes.

What owners reach for while the pipeline matures

Here is the practical reframe. For most dogs, aging is experienced as a mobility story long before it is experienced as a lifespan number. The dog stops taking the stairs. The hind end gets tentative on tile. A soft-tissue injury that would have resolved in a fortnight at four years old is still there at nine. Tendon, ligament, and cartilage are poorly vascularised tissues — they heal slowly even in young dogs, and more slowly with age.

That is the window peptides speak to. BPC-157 is a short peptide sequence derived from a protein identified in gastric juice; published animal research suggests it influences angiogenesis — the formation of new blood vessels — and the behaviour of tendon and ligament fibroblasts, the cells that lay down new collagen. TB-500 is a synthetic fragment related to thymosin beta-4, a naturally occurring protein studied for its role in actin regulation and cell migration, the process by which repair cells reach damaged tissue in the first place. Research suggests these mechanisms may support the body's own repair signalling; owners report using the combination through post-surgical recovery periods and across the slower-moving stiffness of later life.

This is emerging, genuinely promising science that a growing number of owners have adopted. It is also honest to say plainly: BPC-157 and TB-500 are not FDA-approved veterinary drugs, and nothing here is a claim that any product treats, cures, or prevents a condition in your dog.

Where skepticism belongs is the shelf next to it. Plenty of senior-dog chews hide a dozen ingredients behind a proprietary blend, at quantities no study would support, with no batch testing and no certificate of analysis to inspect. pawgen's position on that is simple: publish the formulation, publish third-party testing, use weight-based dosing guidance worked out with your vet, and stand behind it with a 60-day money-back guarantee rather than a marketing story.

Key Takeaways

• LOY-001 is an investigational injectable from Loyal targeting IGF-1 in large and giant breeds. It is not approved and not available for purchase.
• FDA CVM's reasonable-expectation-of-effectiveness finding, announced in November 2023, is one pillar of the conditional approval pathway — not an approval.
• Loyal is privately held. There is no LOY-001 stock, and offers of pre-IPO shares should be treated as suspect.
• Senolytics clear senescent cells; fisetin and dasatinib plus quercetin are the leading candidates, with limited canine-specific data and no approval for dogs.
• Rapamycin works through mTOR, not senescent-cell clearance, and belongs in a separate category.
• Weight control, conditioning, and early veterinary assessment remain the highest-yield levers available to any owner right now.

pawgen publishes third-party certificates of analysis for K9-REPAIR batches at /coas/, lists the full formulation and ingredient breakdown at /shop/, sets out direct-to-door availability at /location/, and covers the wider research background across pawgen.

Finally, the part that does not change regardless of what the pipeline delivers. Your veterinarian owns the diagnosis and the treatment plan — the imaging, the bloodwork, the surgical decision, the prescription. If your dog is on carprofen, gabapentin, a monoclonal antibody for osteoarthritis pain, or anything else, that stays in place unless your vet changes it. Bring your questions about longevity drugs, senolytics, and peptide supplementation to that conversation, with the trial names and the labels in hand. Supplements and peptides operate in the space that proper veterinary care creates — not instead of it.

Owners exploring peptide support for their dog can review K9-REPAIR — BPC-157 + TB-500 formulated for dogs — at https://pawgen.com/. BPC-157 and TB-500 are not FDA-approved veterinary drugs. Nothing in this article treats, cures or prevents any condition; every decision about your dog's care belongs with your veterinarian.